Board of Directors

Mohan is an entrepreneur with a strong track record in the life sciences industry spanning both therapeutics and diagnostics

He has several years of experience in the Pharma industry followed by more than a decade of work as a strategic advisor to various pharmaceutical companies world-wide. After spending 5 years at Roche where he spearheaded formulation of life-cycle pricing strategies for a large number of their products, he built a successful practice at Net Margins which eventually was acquired by Alliance Life Sciences. At Alliance, he was the Global Practice Lead for Pricing and Market Access until 2014. In these challenging assignments, he guided the development of strategies for a number of products across multiple therapeutic areas and markets.

He has been an active entrepreneur and responsible for giving shape to multiple business concepts at the core of new business ventures over the last decade. He designed and developed an Enterprise Price Optimization Software that has now become the leading product used by a large number of major pharma companies. As a co-founder and President of Progentec Diagnostics, he is actively involved in exploring and commercializing new technologies in the diagnostic and therapeutic areas.

He holds a Ph.D. from the Johns Hopkins University with a focus on Pharmaceutical Pricing. Prior to that, he was a Research Fellow at Harvard University.

As VP of Diagnostics, Dr. Sakul leads Pfizer’s Diagnostics programs. Working with Pfizer’s senior leadership, he helped to develop Pfizer’s diagnostics strategy and founded the Diagnostics Group. Under his leadership, companion diagnostics tests accompanied 5 Pfizer drugs to global markets so far. Hakan’s career path included human genetics, statistical genetics, and pharmacogenomics. He led Pfizer’s flagship companion diagnostics program (Xalkori®) to simultaneous drug/diagnostic approvals in 2011.

As member of Board of The Personalized Medicine Coalition, Oncology Advisory Board of Luminex Corp., and Governor Brown’s Advisory Committee on Precision Medicine, his contributions to precision medicine and diagnostics are internationally recognized.

Hakan received BS and MSc degrees from Ankara University, PhD from University of Minnesota (Rotary Foundation Scholar), and conducted postdoctoral studies at University of California. He authored over 30 refereed scientific articles and many other papers. He is keenly interested in diagnostics and related medical technologies to advance individualized healthcare.

Bob Saunders is a General Partner of OCA Ventures and chairs its healthcare investing activity. He represents OCA on the boards of mPulse, ReGroup Therapy and HealthiPass. He is also a Co-Founder and Chairman of XLerateHealth, a healthcare accelerator in Louisville, KY.

Prior to OCA, Bob was a Senior Managing Director and General Partner at Chrysalis Ventures (Louisville) from 1997 to 2009 and served as a Senior Advisor to Chrysalis from 2009-2010. He was also co-founder of Saunders Murdock and Associates, a life science “super-angel” investor, and a Senior Managing Director at Providian Capital Management from 1993-1997. He began his career in business strategy consulting and worked with both The Boston Consulting Group and Bain & Co.

Over the last 30 years, he has invested in several dozen startup companies and has mentored 100+ startups.

Bob received a B.A. from Stanford University, an M.Sc. from the London School of Economics, and an M.A. from Harvard University. Bob is both a Fulbright Scholar and a Marshall Scholar.

Marc is a proven executive and recognized organizational leader with a demonstrated track record of providing reliable business leadership and transaction outcomes within dynamic, fast-paced corporate environments in both public and private companies.

Marc is currently a board member of Pathfinder Health a digital-health company focused on autism and developmental delay in children and most recently Marc was the COO & CFO of binx health a first-of-kind, commercial, growth-stage healthcare technology and molecular diagnostics company that makes routine diagnostic testing convenient through its proprietary omnichannel platforms including its point-of-care io platform, which puts central-lab quality diagnostic testing solutions in the hands of clinicians everywhere, and its binx everywhere, digital-based platform (which Marc co-founded), a suite of medical guideline-driven, at-home sample collection offerings, bringing high-quality diagnostic testing and population health tools to broad and under-served patient populations. While at binx, Marc raised ~$120M in equity and debt capital.

Immediately before binx, Marc was the COO & CFO of Good Start Genetics, a leading molecular genetics information company transforming the standard of care in fertility medicine, where he drove the successful turnaround of the company and its ultimate acquisition by Invitae (NASDAQ: NVTA) in Aug ‘17. Prior to Good Start Marc was CFO of T2 Biosystems, where he led the company's preparation for and completion of an IPO and raised nearly $100M ($70M equity + $30M in debt); he built the finance team and implemented the necessary infrastructure and processes required of a public company, and he helped drive the commercialization of the company's first FDA approved product. Previously, Marc was CFO of Crashlytics, where he oversaw the company's acquisition by Twitter (was the largest acquisition of any company by Twitter at that time). Marc was CFO of Ivenix (acquired by Fresenius) and Interim-Executive Chairman (Jan '13-Feb '14) where he led all finance, admin and operations functions, including raising $8M in capital. Before that, Marc served as CFO of CHiL Semiconductor, where he oversaw growth from pre-revenue to a $20M run-rate, raised $30M in venture financing, and the ultimate acquisition of the company in March 2011. Prior to CHiL, Marc held multiple senior positions at Picis, where he helped grow the company from < $20M to > $100M in annual revenue.

As President and CEO, Scott Meacham leads i2E’s efforts to create knowledge-based jobs in Oklahoma through the development of and investment in high growth companies.

Scott comes to i2E from the Crowe & Dunlevy law firm, which he joined in January 2011 as a shareholder and director. He served as chairman of the banking and financial institutions practice group. Prior to that, he served as the 17th State Treasurer of Oklahoma, an office he held from June 2005 until January 2011.

In addition to his duties as State Treasurer, Scott served on the governor’s cabinet as Secretary for Finance and Revenue from January 2003 until January 2011. In this capacity, he was the governor’s primary financial and budget advisor and served as the governor’s chief negotiator on budget, legislative, tribal and other matters.

Scott formerly served as Chief Executive Officer, General Counsel and Lending Supervisor of First National Bank & Trust of Elk City. Under his leadership, the bank more than doubled in size and saw its profits increase by more than 150 percent. He assumed executive leadership of the bank in 1991 and served as the bank’s general counsel since 1989. He continues to be associated with the bank as a member and secretary of the board of directors and a member of the loan, investment and executive committees.

A fifth generation Oklahoman and a graduate of Chickasha High School, Scott holds a Bachelor’s degree in finance, a Masters of Business Administration and a law degree, all from the University of Oklahoma.

Mary Jo Williamson is chief administrative officer of Mayo Clinic’s diagnostic business lines, which include Mayo Clinic Laboratories and Mayo Clinic’s Cardiac Monitoring. Mayo Clinic Laboratories is the global leader in turning test results into clinical answers by providing advanced testing and pathology services for healthcare organizations in partnership with Mayo Clinic’s Department of Laboratory Medicine and Pathology.

Ms. Williamson has served as chief administrative officer of Mayo Clinic in Rochester, responsible for Mayo Clinic in Rochester clinical activities. In addition, she also has served as chief administrative officer of Mayo Clinic Health System, a network of 16 community hospitals and 53 multispecialty clinics across 44 communities in Minnesota, Wisconsin, and Iowa.

Ms. Williamson previously was chair of Practice Administration at Mayo Clinic and director of the Mayo Clinic Care Network, a collaboration to share Mayo’s clinical knowledge and expertise with select healthcare organizations around the globe. During her over 30-year career with Mayo Clinic, Ms. Williamson has held various leadership roles across the Midwest, as well as at Mayo Clinic in Arizona and Mayo Clinic in Florida. She helped develop the Ask Mayo Clinic nurse triage service and was vice chair for Contracting and Payer Relations and Mayo Clinic Health System.

Ms. Williamson also has been a member of the Mayo Clinic Management Team, Mayo Clinic Clinical Practice Committee, Midwest Executive Operations Team, Mayo Clinic Administrative Team, the Mayo Clinic Board of Governors, and the Mayo Clinic Board of Trustees. Prior to Mayo Clinic, she worked in the Strategic Services Division of Anderson Consulting and as director of Budgeting for Rose Medical Center in Denver.

Ms. Williamson holds a Bachelor of Science in finance and accounting from Arizona State University and an MBA from Southern Methodist University. In addition to her Mayo Clinic responsibilities, she serves on the boards of the Minnesota Chamber of Commerce, American Medical Group Association, IKS Health, and Resoundant Inc.